Matrix metalloproteinase inhibitor RECK expression in canine tumors

Journal of Veterinary Medical Science

Volumn 67, Issue 8, 2005, Pages 761-767

  Takagi, Satoshi ^a   Kato, Yuka ^b   Asano, Kazushi ^a   Ohsaki, Tomohiro ^a   Bosnakovski, Darko ^a   Hoshino, Yuki ^a   Okumura, Masahiro ^a   Kadosawa, Tsuyoshi ^a   Fujinaga, Toru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Canine; Matrix metalloproteinase; Proteinase inhibitor; RECK; Tumor malignancy

Indexed keywords

GELATINASE B; MEMBRANE PROTEIN; MESSENGER RNA; PRIMER DNA;

ANIMAL; ANIMAL DISEASE; ARTICLE; COMPARATIVE STUDY; DOG; DOG DISEASE; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEOPLASM; NONPARAMETRIC TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; DNA PRIMERS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

CANIS FAMILIARIS;

EID: 25644446137     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.67.761     Document Type: Article

References (37)

1. Barroga, E. F., Kadosawa, T., Okumura, M. and Fujinaga, T. 1999. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J. Vet. Med. Sci. 61: 361-367.
2. Becerril, C., Pardo, A., Montano, M., Ramos, C., Ramirez, R. and Selman, M. 1999. Acidic fibroblast growth factor induces an antifibrogenic phenotype in human lung fibroblasts. Am. J. Respir. Cell. Mol. Biol. 20: 1020-1027.
3. Cawston, T. E. 1996. Metalloproteinase inhibitors are the prevention of connective tissue breakdown. Pharmacol. Ther. 70: 163-182.
4. Chomczynski, P. and Sacchi, N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
5. Dalberg, K., Eriksson, E. and Enberg, U. 2000. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J. Surg. 24: 334-340.
6. de las Mulas, M. J., Ordas, J., Millan, Y., Fernandez-Soria, V. and Ramony, C. S. 2003. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res. Treat. 80: 363-367.
7. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H. and Augustin, H. G. 2000. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60: 1388-1393.
8. Farina, A. R., Tacconelli, A., Vacca, A., Maroder, M., Gulino, A. and Mackay, A. R. 1999. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ. 10: 353-367.
9. Foda, H. D. and Zucker, S. 2001. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov. Today 9: 478-482.
10. Furumoto, K., Arii, S., Mori, A., Furuyama, H., Gorrin Rivas, M. J., Nakao, T., Isobe, N., Murata, T., Takahashi, C., Noda, M. and Imamura, M. 2001. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing-cysteine-rich protein with Kazal motifs. Hepatology 33: 189-195.
11. Gasson, J. C., Golde, D. W., Kaufman, S. E., Westbrook, C. A., Hewick, R. M., Kaufman, R. J., Wong, G. G., Temple, P. A., Leary, A. C. and Brown, E. L. 1985. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature (Lond.) 315: 768-771.
12. Ishiguro, T., Kadosawa, T., Mori, K., Takagi, S., Okumura, M. and Fujinaga, T. 2001. Establishment and characterization of a new canine mast cell tumor cell line. J. Vet. Med. Sci. 63: 1031-1034.
13. John, A. and Tuszynski, G. 2001. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 7: 14-23.
14. Kadosawa, T., Nozaki, K., Sasaki, N. and Takeuchi, A. 1994. Establishment and characterization of a new cell line from a canine osteosarcoma. J. Vet. Med. Sci. 56: 1167-1169.
15. Kawamata, H., Uchida, D. and Hamano, H. 1998. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int. J. Oncol. 13: 699-704.
16. Kawano, N., Osawa, H. and Takaaki, I. 1997. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms. Hum. Pathol. 28: 613-622.
17. Lana, S. E., Oglivie, G. K., Hnsen, R. A., Powers, B. E., Dernell, W. S. and Withrow, S. J. 2000. Identification of matrix metalloproteinases in canine neoplastic tissue. Am. J. Vet. Res. 61: 111-114.
18. Loukopoulos, P., Mungall, B. A., Straw, R. C., Thornton, J. R. and Robinson, W. F. 2003. Matrix metalloproteinase-2 and -9 involvement in canine tumors. Vet. Pathol. 40: 382-394.
19. Lu, X. Q., Levy, M., Weinstein, I. B. and Santella, R. M. 1991. Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer. Cancer Res. 51: 6231-6235.
20. Mannello, F. and Gazzanelli, G. 2001. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 6: 479-482.
21. Masui, T., Doi, R., Koshiba, T., Fujimoto, K., Tsuji, S., Nakajima, S., Koizumi, M., Toyoda, E., Tulachan, S., Ito, D., Kami, K., Mori, T., Wada, M., Noda, M. and Imamura, M. 2003. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin. Can. Res. 9: 1779-1784.
22. Mimori, K., Mori, M., Shiraishi, T., Fujie, T., Baba, K., Haraguchi, M., Abe, R., Ueo, H. and Akiyoshi, T. 1997. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br. J. Cancer 76: 531-536.
23. Mohammed, S. I., Bennett, P. F., Craig, B. A., Glickman, N. W., Mutsaers, A. J., Snyder, P. W., Widmer, W. R., DeGortari, A. E., Bonney, P. L. and Knapp, D. W. 2002. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 62: 356-358.
24. Nagase, H., Suzuki, K., Itoh, Y., Kan, C. C., Gehring, M. R., Huang, W. and Brew, K. 1996. Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Adv. Exp. Med. Biol. 389: 23-31.
25. Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D. B., Ide, C., Horan, T. P., Arakawa, T., Yoshida, H., Nishikawa, S., Itoh, Y., Seiki, M., Itohara, S., Takahashi, C. and Noda, M. 2001. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107: 789-800.
26. Owen, L. N. 1980. TNM classification of tumors in domestic animals, 1st ed., (Owen, L. N., ed.), World Health Organization, Geneva, Switzerland.
27. Sasahara, R. M., Takahashi, C. and Noda, M. 1999. Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem. Biophys. Res. Commun. 264: 668-675.
28. Sato, H., Kida, Y., Mai, M., Endo, Y., Sasaki, T., Tanaka, J. and Seiki, M. 1992. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7: 77-83.
29. Sato, H. and Seiki, M. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395-405.
30. Span, P. N., Sweep, C. G., Manders, P., Beex, L. V., Leppert, D. and Lindberg, R. L. 2003. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 91: 2710-2715.
31. Stetler-Stevenson, W. G. 2001. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg. Oncol. Clin. New. Am. 10: 383-392.
32. Takahashi, C., Sheng, Z., Horan, T. P., Kitayama, H., Maki, M., Hitomi, K., Kitaura, Y., Takai, S., Sasahara, R. M., Horimoto, A., Ikawa, Y., Ratzkin, B. J., Arakawa, T. and Noda, M. 1998. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. U.S.A. 95: 13221-13226.
33. Takagi, S., Kitamura, T., Hosaka, Y., Ohsaki, T., Bosnakovski, D., Kadosawa, T., Okumura, M. and Fujinaga, T. 2004. Molecular cloning of canine membrane-anchored inhibitor of matrix metalloproteinase, RECK. J. Vet. Med. Sci. (in press)
34. Thamm, D. H. and Vail, D. M. 2001. Mast cell tumors. pp. 261-282. In: Small Animal Clinical Oncology, 3rd ed. (Withrow, S. J. and MacEwin, E. G., eds.), W. B. Saunders, Philadelphia.
35. Toth, M., Bernardo, M. M., Gervasi, D. C., Soloway, P. D., Wang, Z., Bigg, H. F., Overall, C. M., DeClerck, Y. A., Tschesche, H., Cher, M. L., Brown, S., Mobashery, S. and Fridman, R. 2000. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J. Biol. Chem. 275: 41415-41423.
36. Tsuruda T., Boerrigter G., Huntley B.K., Noser J.A., Cataliotti A., Costello-Boerrigter L.C., Chen H.H. and Burnett Jr. J.C. 2002. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res. 91: 1127-1134.
37. Wittwer, C. T., Ririe, K. M., Andrew, R. V., David, D. A., Gundry, R. A. and Balis, U. J. 1997. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 22: 176-181.